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Background: The safety and efficacy of the unrestricted use of sirolimus-eluting stents (SES) versus paclitaxel-eluting stents (PES) in the setting of 
acute myocardial infarction (AMI) still need further clarification in larger study population.
Methods: A total of 2474 AMI patients who underwent percutaneous coronary intervention (PCI) with SES (n=1264), or PES (n=1210) were enrolled 
from Korea Acute Myocardial Infarction Registry (KAMIR). The composite clinical outcomes at 1 year were compared between the 2 groups. Target 
lesion failure (TLF) was defined as the composite of cardiac death, target lesion recurrent nonfatal myocardial infarction (Re-MI), or target lesion 
revascularization (TLR). Total major adverse cardiac events (MACE) included total death, Re-MI, and target vessel revascularization (TVR).
Results: The two groups had similar baseline characteristics. The 1-year clinical outcomes showed that although the 2 group did not differ 
significantly in the incidences of cardiac death, total death, Re-MI, TVR, total MACE and stent thrombosis, SES group had significantly lower 
incidences of TLR (1.8% vs 3.1%, P=0.034) and TLF (7.9% vs 10.2%, P=0.043) as compared with PES group. Furthermore, SES group showed a trend 
toward significantly lower incidence of definite stent thrombosis (0.9% vs 1.7%, P=0.080) compared to PES group. Multivariable Cox regression 
analysis showed that compared to PES, SES was independently associated with lower incidences of TLR [odds ratio (OR) 0.55, 95% confidence 
interval (CI) 0.32-0.93, P=0.027] and TLF (OR 0.70, 95% CI 0.52-0.94, P=0.020) at one year. But SES failed to be an independent predictor of other 
adverse clinical outcomes.
Conclusions: Despite the similar incidences of cardiac death, total death, Re-MI, TVR, total MACE and stent thrombosis, SES seems to be superior 
to PES in reducing TLR and TLF in AMI patients at one year.
